- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-PGS2/ DCN/ CSCD functional antibody
Anti-PGS2/ DCN/ CSCD functional antibody for cell culture, ELISA & in-vivo assay
Go to DCN/DCN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T67883-Ab-1/ GM-Tg-hg-T67883-Ab-2 | Anti-Human DCN monoclonal antibody | Human |
| GM-Tg-rg-T67883-Ab-1/ GM-Tg-rg-T67883-Ab-2 | Anti-Rat DCN monoclonal antibody | Rat |
| GM-Tg-mg-T67883-Ab-1/ GM-Tg-mg-T67883-Ab-2 | Anti-Mouse DCN monoclonal antibody | Mouse |
| GM-Tg-cynog-T67883-Ab-1/ GM-Tg-cynog-T67883-Ab-2 | Anti-Cynomolgus/ Rhesus macaque DCN monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T67883-Ab-1/ GM-Tg-felg-T67883-Ab-2 | Anti-Feline DCN monoclonal antibody | Feline |
| GM-Tg-cang-T67883-Ab-1/ GM-Tg-cang-T67883-Ab-2 | Anti-Canine DCN monoclonal antibody | Canine |
| GM-Tg-bovg-T67883-Ab-1/ GM-Tg-bovg-T67883-Ab-2 | Anti-Bovine DCN monoclonal antibody | Bovine |
| GM-Tg-equg-T67883-Ab-1/ GM-Tg-equg-T67883-Ab-2 | Anti-Equine DCN monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T67883-Ab-1/ GM-Tg-hg-T67883-Ab-2; GM-Tg-rg-T67883-Ab-1/ GM-Tg-rg-T67883-Ab-2; GM-Tg-mg-T67883-Ab-1/ GM-Tg-mg-T67883-Ab-2; GM-Tg-cynog-T67883-Ab-1/ GM-Tg-cynog-T67883-Ab-2; GM-Tg-felg-T67883-Ab-1/ GM-Tg-felg-T67883-Ab-2; GM-Tg-cang-T67883-Ab-1/ GM-Tg-cang-T67883-Ab-2; GM-Tg-bovg-T67883-Ab-1/ GM-Tg-bovg-T67883-Ab-2; GM-Tg-equg-T67883-Ab-1/ GM-Tg-equg-T67883-Ab-2 |
| Products Name | Anti-DCN monoclonal antibody |
| Format | mab |
| Target Name | DCN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-DCN benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T67883-Ag-1 | Recombinant multi-species PGS2/ DCN/ CSCD protein |
| ORF Viral Vector | vGMAP000037 | Human DCN Adenovirus particle |
| ORF Viral Vector | pGMLP001350 | human NM_001920humanNM_001920 Lentivirus plasmid |
| ORF Viral Vector | pGMAP000037 | Human DCN Adenovirus plasmid |
| ORF Viral Vector | pGMAD000132 | human DCN Adenovirus plasmid |
| ORF Viral Vector | vGMAD000132 | human DCN Adenovirus particle |
| ORF Viral Vector | vGMLP001350 | human NM_001920humanNM_001920 Lentivirus particle |
| ORF Viral Vector | pGMLPm001658 | mouse Dcn Lentivirus plasmid |
| ORF Viral Vector | vGMLPm001658 | mouse Dcn Lentivirus particle |
Target information
| Target ID | GM-T67883 |
| Target Name | DCN |
| Gene ID | 1634,13179,29139,709933,403904,101101236,280760,100034120 |
| Gene Symbol and Synonyms | CSCD,DC,DCN,DSPG2,PG40,PGII,PGS2,SLRR1B |
| Uniprot Accession | P07585,Q01129,Q29393,P21793,O46542 |
| Uniprot Entry Name | PGS2_HUMAN,PGS2_RAT,PGS2_CANLF,PGS2_BOVIN,PGS2_HORSE |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000011465 |
| Target Classification | N/A |
The target: DCN, gene name: DCN, also named as CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B. This gene encodes a member of the small leucine-rich proteoglycan family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature protein. This protein plays a role in collagen fibril assembly. Binding of this protein to multiple cell surface receptors mediates its role in tumor suppression, including a stimulatory effect on autophagy and inflammation and an inhibitory effect on angiogenesis and tumorigenesis. This gene and the related gene biglycan are thought to be the result of a gene duplication. Mutations in this gene are associated with congenital stromal corneal dystrophy in human patients. [provided by RefSeq, Nov 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
